Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

MEPC Gets Green Light for UK’s First New Office and Laboratory Development Since the EU Referendum

03 October 2016: Abingdon, UK - MEPC has secured planning consent at Milton Park in Oxfordshire for the first speculative office and laboratory development to be submitted and approved in the UK since the EU Referendum in June. As a result, MEPC will be pressing the button to build three new high specification buildings totalling 110,000 sq ft, which will be completed by late 2017.

Read the rest of entry »

Chancellor Announces £220 million for Cutting-edge New Technology

01 October 2016: London, UK - Philip Hammond has today (1 October 2016) unveiled a package of support which includes £220 million for the life science and university sectors to help technology breakthroughs translate into commercial success, as well as action to ensure disruptive businesses thrive in the UK.

Read the rest of entry »

PCI Pharma Services Welcomes Jens Peter Nielsen as Business Development Manager at its Hay-on-Wye, UK Site

29 September 2016: Hay on Wye, UK – Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Jens Peter Nielsen as Business Development Manager in its European commercial packaging team, which includes its Hay-on-Wye site in Wales, UK, and a recognized center of excellence for packaging, one of four locations in Europe.

Read the rest of entry »

Sareum Announce Licence agreement for Chk1 Inhibitor CCT245737

27 September 2016: Cambridge, UK - Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that its co-investment partner, the CRT Pioneer Fund, has today licensed exclusive and worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics, Inc. (NASDAQ: DNAI).

Read the rest of entry »

OBN Announces New Health and Life Sciences Event in Partnership with the West Sussex Health and Life Sciences Cluster

26 September 2016, Abingdon, UK: OBN, the leading membership organisation supporting the UK’s innovative life sciences companies, and the West Sussex Health and Life Sciences Cluster (WSHLSC) announced today that they are launching a top-quality funding and export support event in West Sussex aimed at health and life science companies.

Read the rest of entry »

Summit Receives Fast Track Designation from US FDA for Ezutromid

<p>26 September 2016: Oxford, UK.  Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and <i>Clostridium difficile</i> infection, today announces it has received Fast Track designation from the US Food and Drug Administration ('FDA') for ezutromid in the treatment of DMD. Ezutromid is a utrophin modulator and represents a potential disease modifying treatment for all patients with the fatal muscle wasting disease DMD.</p>

Read the rest of entry »

PCI to Share Expertise in Serialization and Safe Handling of Potent Molecules at CPHI Worldwide

20 September 2016: Philadelphia, USA – Leading pharmaceutical provider PCI Pharma Services will bring its expertize to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) with two Speakers Corner slots at the ICSE Exhibitor Showcase.

Read the rest of entry »

Wickham Labs to Exhibit at Medtec Ireland 2016

22 September 2016: Gosport, UK - Wickham Laboratories Ltd will exhibit on Stand 305 at Medtec Ireland, October 4-5.

Read the rest of entry »

Physiomics Placing and Update on Acquisition

21 September 2016 - Physiomics announces that it has completed a placing, conditional only on Admission, to raise £555,000.00 from the issue of 2,220,000,000 new ordinary shares of 0.004p each ("Ordinary Shares") at a price of 0.025p per share, through Hybridan LLP (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealing is expected to commence on 28th September 2016.

Read the rest of entry »

New Heparan Sulfate Antibodies Applications Guide

20 September 2016: Abingdon, UK - AMSBIO has produced a new 24-page guide that brings together applications, protocols, results and citations to provide an informative resource for researchers using heparan sulfate antibodies.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.